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Background: One in every 9 persons age 65 years and older and 1 in every 3 persons 
age 85 years and older has Alzheimer’s disease. The etiology of the disease is not well 
understood. For decades, cerebral accumulation of amyloid proteins and tau 
neurofibrillary tangles has been thought to be the culprit. While amyloid and tau are still 
risk factors, mounting evidence is shifting the framing of Alzheimer’s to a disease of 
disordered metabolism. Individuals with Alzheimer’s consistently exhibit decreased 
cerebral metabolism due to impaired glucose utilization. Those with chronic 
hyperglycemia present with greater accumulation of cerebral amyloid plaques and more 
severe reductions in brain metabolism increasing Alzheimer’s risk. Little data exist 
exploring the role of dietary intake, namely carbohydrate intake and glycemic load, in 
amyloid processing or altering brain bioenergetics through manipulation of dietary 
macronutrient intake. 
Methods: Two studies were conducted to assess the questions proposed in this 
dissertation. First, we performed cross-sectional analyses of dietary glycemic measures 
(high glycemic load diet pattern [HGLDiet], sugar intake, carbohydrate intake and 
glycemic load) with cerebral amyloid burden (measured by florbetapir F-18 PET) and 
cognitive performance in 128 cognitively normal older adults participating in the 
University of Kansas Alzheimer’s Prevention Program. Second, we recruited 15 
participants with a diagnosis of Alzheimer’s disease to a single-arm clinical trial of a 
medium chain triglyceride supplemented ketogenic diet (MCT-KD) for 3 months to 
assess feasibility and obtain preliminary efficacy data. At month 3, participants 
terminated the MCT-KD and resumed a normal diet for a 1-month washout period. 
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Ketone generation was monitored through daily checking of urinary ketone status by the 
participant and monthly serum β-hydroxybutyrate assessment. Dietary intake was 
collected through monthly 3-day food records. Cognition was measured through 
administration of the Mini-Mental State Exam and the Alzheimer’s Disease Assessment 
Scale-cognitive subscale at baseline, after 3 months of the dietary intervention and 
following a 1-month discontinuation of the MCT-KD. 
Results: In the observational study, individuals with elevated amyloid had greater 
consumption of the HGLDiet pattern (p=0.015). The HGLDiet pattern was positively 
associated with amyloid burden both globally and in all regions of interest independent 
of age, gender, and BMI (all p-values ≤ 0.001). Individual dietary glycemic measures 
(sugar intake, carbohydrate intake and glycemic load) were also positively associated 
with global amyloid load and nearly all regions of interest independent of age, gender 
and BMI (p-values ≤ 0.05). Higher sugar consumption was associated with poorer 
global cognitive performance (Global Composite and Mini-Mental State Exam) and 
performance on subtests of Digit Symbol, Trailmaking B, and Block Design when 
controlled for age, gender, and education. In the clinical trial, the MCT-KD was feasible 
in individuals with AD as 10 of the 15 participants produced urinary and serum ketones 
during the 3-month intervention. Urinary acetoacetate was detected an average of 54.5 
(60.6%) days of the intervention in study completers. Serum β-hydroxybutyrate was 
significantly elevated above baseline at all 3 monthly time points during the diet 
intervention (p≤0.001 for each). Improvements in ADAS-cog scores were observed from 
baseline to month 3 (4.1 point mean improvement, p=0.02) and improvements 
diminished after the 1-month washout. 
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Conclusion: A dietary pattern high in carbohydrate, especially highly glycemic 
carbohydrates, was associated with biomarkers for AD risk. A ketogenic diet restricted 
in carbohydrate and higher in fat may elicit cognitive benefit in individuals already 
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 In the US, Alzheimer’s disease (AD) is the most common form of dementia and 
affects an estimated 5.4 million Americans or 1 of every 9 people over the age of 65. AD 
accounts for 60 to 80 percent of the total cases of dementia (1). Apart from the personal 
burden of AD, this disease also drastically affects the nation economically costing an 
estimated $457 billion in 2016 (1). Future predictions of the effect of AD are also quite 
staggering. If no progress is made in altering the course of AD onset and progression, it 
is estimated that nearly 14 million people will have AD by 2050 with a cost of over $1 
trillion each year (2). Furthermore, the toll of AD is magnified when physical and 
emotional burden placed on caregivers and family members is considered (3, 4). 
 AD is a progressive neurodegenerative disease that is not a normal aspect of 
aging, although the greatest risk factor for the development of AD is age (1). It is 
characterized by formation of plaque lesions from abnormal cerebral accumulation of 
amyloid-beta (Aβ) proteins, accumulation of neurofibrillary tau protein tangles and 
progressive brain atrophy resulting in significant reduction in brain volume (5). 
Symptoms include progressive cognition and memory impairment, changes in behavior, 
depression and decline in ability to carry out daily activities (5, 6). 
 The etiology of Alzheimer’s disease is not well understood (7). Evidence 
suggests that a myriad of determinants could likely contribute to AD pathology. Several 





AD as a Metabolic Disease 
 The long-standing theory of AD etiology posits that abnormal Aβ accumulation in 
the brain drives the progression of AD (8). Individuals can, however, exhibit normal 
cognition in the presence of Aβ plaques, indicating that they alone are not sufficient to 
cause dementia and may not be accurate biomarkers of severity of the disease.(9) 
More recently, mitochondrial dysfunction has been proposed as a factor in the 
pathogenesis of AD (8, 10-12). Consistent evidence supports significant metabolic 
disruption that occurs early in the progression of AD, potentially presenting before the 
onset of clinical symptoms (13, 14). A significant source of energy is required for proper 
brain function, which in normal individuals is typically provided by glucose derived from 
carbohydrate consumed in the diet. Individuals with AD exhibit a consistent decrease in 
brain glucose utilization (15-19). 
Support for the mitochondrial-related hypotheses for AD has increased based on 
the use of cytoplasmic hybrid (cybrid) techniques (20, 21). Cybrid cells are produced by 
fusing enucleated cells containing mitochondrial DNA (mtDNA) with nucleated cells 
replete of mtDNA (20). MtDNAs transfer to the nucleated cells, replicate and establish 
aerobic metabolism (20). Models in which cybrids containing mtDNA of platelets from 
patients with AD or MCI compared to age-matched healthy controls demonstrate 
significantly decreased respiratory metabolism in the AD cybrids (22-25). These findings 
suggest that mitochondria and mtDNA are complicit in bioenergic deficits observed in 
AD. 
It is not known whether the metabolic impairment observed in AD is cause or 
consequence in the pathogenesis of the disease, although many have hypothesized the 
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former. Nevertheless, there is great interest in mitochondrial and metabolic targeting in 
the treatment of AD (26). Manipulation of energetic substrates through diet may be a 
potentially effective therapeutic or preventive approach to AD (27). 
 
Normal Brain Energy Metabolism 
The brain demands 20% or more of total body energy (28, 29). In normal brain 
metabolism, glucose serves as the major cerebral energy substrate. The Western diet 
commonly contains 50-65% of total energy as carbohydrate (30). Carbohydrates from 
the diet are converted to glucose primarily destined for meeting energy metabolism 
demands. Glucose is transported across the endothelium of the blood-brain barrier via 
the non-insulin dependent glucose transporter, GLUT 1. It then enters either astrocytes 
via GLUT 1 or neurons via GLUT 3, which are not insulin dependent. Neuronal energy 
metabolism is the major focus of underlying brain energy metabolism, although some 
neuronal metabolism may depend on substrate production by the astrocyte (31). In the 
neuron, the inner-mitochondrial electron transport chain (ETC) is the primary source of 
cerebral ATP production. The ETC consists of five complexes (Complex I-V), which 
completely oxidize glucose to carbon dioxide and water and create an inner-
mitochondrial proton gradient change that drives ATP production. A disruption in any 
complex of the ETC can cause serious energy perturbations in the brain energy flux. 
 
Glucose Metabolism Impairment in AD 
There is a clear link between AD and cerebral glucose utilization impairment (26). 
This impairment is exhibited early in AD and may even present prior to onset of AD 
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symptomology (13, 14). Positron emission tomography (PET), using fluordeoxyglucose 
(FDG) as a marker, allows measurement of glucose uptake into brain tissue and 
subsequently provides insight into glucose metabolism in the brain known as the 
cerebral metabolic rate of glucose (CMRg) (32). Normal brain CMRg is approximately 
100-120g/day (33). During the course of healthy aging, CMRg is known to decrease by 
12-15% (34). Alzheimer’s disease appears to have an even greater effect on CMRg. 
Compared to age matched older adults with normal cognition, mild AD patients 
exhibited a 20-25% global reduction in brain CMRg and regional reductions as high as 
33% (34, 35). Hypometabolism of the primary systemic energy substrate could elicit 
cerebral energy crisis expediting neuronal deterioration and cognition impairment. 
Several factors have been investigated as major contributors to the hypometabolic state 
exhibited in AD.  
In the brain, glucose uptake is primarily mediated by non-insulin dependent 
GLUT 1 and GLUT 3 transporters, both known to have decreased expression in AD (36, 
37). Insulin-dependent Insulin Receptor and GLUT 4 are expressed in neurons of the 
hippocampus, a region integral to learning and memory in mammals (38). Glucose-
mediated increases in plasma-insulin levels induce GLUT 4 translocation in the rat 
hippocampus, indicating an important role for insulin in hippocampal brain glucose 
metabolism (39, 40). Many metabolic conditions influence insulin sensitivity and are 
quite prevalent in the United States, including type 2 diabetes and obesity (41). 
Systemic and, in turn, regional cerebral reductions in insulin sensitivity could influence 
hippocampal glucose utilization (42). 
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 Mitochondrial dysfunction is a leading theory for the pathology of AD. The 
mitochondrion houses the ETC and is the primary contributor of neuronal ATP. 
Alterations in the expression of mitochondrial DNA (mtDNA) appear to have a profound 
effect on ETC activity (26). In vitro studies using cells from both humans and mice 
exhibit common abnormalities in the mitochondria of AD, including downregulation of 
genes encoding for NADH dehydrogenase (complex I) and cytochrome c-oxidase 
(complex IV) of the ETC (43, 44). Furthermore, the brains of individuals with AD exhibit 
downregulation in expression of mitochondrial enzymes crucial for energy production 
(45). At this time, the cause of mitochondrial defects in AD is unclear. Inherited mtDNA 
is proposed as a determinant of baseline mitochondrial function (26). If defective mtDNA 
is inherited, the mitochondria have a decreased ability to produce ATP. Oxidative stress 
from reactive oxygen species (ROS) is also known to elicit damaging effects on 
mitochondria (46, 47). The mitochondria are large contributors to cerebral ROS 
production, which is typically reduced by local antioxidant systems prior to oxidative 
stress. If defects in the ETC exist, mitochondrial production of ROS is likely upregulated 
and could potentially lead to further ROS-mediated ETC disruption (48). Evidence 
indicates that inhibited mitochondrial function also likely influences upregulation of Aβ 
deposition (26), which has been shown to deposit in the mitochondria of the neurons 
and further inhibit the ETC (49). As multiple factors play a detrimental role in 





Dietary Factors and AD 
 As it becomes more clear that metabolism is either a factor in AD pathology or 
affected by its development, interest in the relationship between diet and AD has 
increased. 
Studying the role of nutrition in disease states can be difficult. Studies often focus 
on the relationships of a single or handful of nutrients to outcomes, which is valuable, 
but may exclude interactive or synergistic effects of foods and nutrients. For the full 
scope of dietary impact, in addition to solitary nutrients, identification of dietary patterns 
can explore the synergistic effects of foods and nutrients and account for potential food 
interrelatedness (30, 50). Although single nutrients have been studied with mixed 
reports in AD epidemiological and clinical trials, epidemiological studies of dietary 
patterns have been most compelling and will be the primary focus of this review. 
 The Western diet pattern was originally described by Hu et al. through the use of 
principal components analysis (PCA) (30). Consisting of high intake of red meat, refined 
grains, processed meat, high-fat dairy products, dessert, sugary beverages, eggs, 
french fries and potatoes, the Western diet is predictive of type 2 diabetes and other 
conditions of impaired peripheral metabolism (51, 52) that are risk factors for AD as 
discussed below. A Western dietary pattern is also strongly correlated with AD 
incidence (53) and has negatively affects brain structure, neuronal generation and 
cognitive function (54-56). 
 The Mediterranean dietary pattern stands in clear contrast to the Western dietary 
pattern with high intake of fruits, vegetables, legumes and cereals; moderate 
consumption of oily fish and dairy; and low consumption of meat, sugar and saturated 
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fat. Most dietary fat in this diet pattern comes from olive oil. Wine is consumed in 
moderation with meals (57). Epidemiological data suggest that adherence to the 
Mediterranean diet is inversely correlated with insulin resistance (58), inflammation that 
causes oxidative stress (59, 60) and risk of AD (57, 61). 
 Researchers at Rush University identified the Mediterranean-Dietary Approaches 
to Stop Hypertension Intervention for Neurodegenerative Delay (MIND diet) through 
epidemiological data (62). The MIND diet is a dietary pattern that combines the 
Mediterranean dietary pattern and the Dietary Approaches to Stop Hypertension diet 
(DASH diet) (62). AD risk appears to be diminished in a step-wise fashion dependent on 
an individual’s MIND diet adherence score (62). The MIND diet focuses, particularly, on 
15 food components that are simply broken into “brain health food groups” and 
“unhealthy food groups” (Table 1). 
Table 1 MIND Diet Food Groups 
Brain Healthy Food Groups Unhealthy Food Groups 
Green leafy vegetables Red meats 
Other vegetables Butter and stick margarine 
Nuts Cheese 
Berries Pastries and sweets 
Beans Fried or fast food 
Whole grains  
Fish  
Poultry  
Olive oil  
Wine  
  
Novel Aβ Imaging and Relationship with Nutrients 
 In vivo positron emission tomography (PET) imaging for quantification of cerebral 
Aβ deposition as an objective outcome biomarker in AD studies is a recent trend (63). 
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Aβ can be measured in PET images through administration of either 11C Pittsburgh 
Compound B (PiB) or Florbetapir (18F), radiopharmaceutical compounds that bind Aβ 
(64). Approximately 30% of cognitively normal older adults exhibit elevated amyloid 
burden while the prevalence of elevated amyloid burden in MCI and AD is 60% and 
90%, respectively (63). 
 An emerging field of study, few studies relate nutrients to PET identified amyloid 
burden. Mosconi et al. (65) published a pilot study that investigated the relationship 
between nutrient intake and amyloid burden in 49 non-demented adults. Higher intakes 
of vitamin B12, vitamin D and omega-3 fatty acids were associated with attenuated 
deposition of Aβ. Although the study used exploratory statistical procedures, it serves as 
proof of concept for investigating the relationship of diet and amyloid burden. Berti et al. 
(66) investigated the relationship between nutrient patterns and amyloid burden in 52 
cognitively normal adults. Thirty-five nutrient variables were used as input into principal 
components analyses and 5 distinct dietary nutrient patterns were identified. An inverse 
relationship was exhibited between amyloid burden and the dietary pattern with high 
loading coefficients for vitamin B12, vitamin D and zinc, suggesting a role for these 
nutrients, potentially synergistically, in preventing Aβ accumulation. 
 Further suggesting a relationship between Aβ processing and nutrition, two 
studies investigated correlation between serum nutrient status and amyloid burden. In a 
cohort of 73 cognitively normal older adults, Morris et al. demonstrated that elevated 
fasting serum glucose was strongly associated with elevated amyloid burden (67). 
Yassine et al. showed a significant inverse relationship between serum docosahexanoic 
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acid status, an omega-3 fatty acid commonly found in fatty fish, and cerebral Aβ burden 
in a cohort of 61 older adults with either normal cognition or MCI (68). 
 The clinical relevance of Aβ is not precisely defined, but elevated accumulation is 
a known risk factor and likely part of the complex pathology of AD (69). Cerebral 
amyloid quantification techniques have opened the door to a better understanding of 
factors that affect Aβ processing and, in turn, risk of AD. Mounting evidence suggests a 
possible role for nutrition in amyloid protein processing, however, we’ve only scratched 
the surface of potential for investigating these relationships. 
 
Impaired Glycemia/Insulin Resistance and Brain Metabolism 
 Metabolic disorders such as type 2 diabetes are known risk factors for AD. 
Individuals with type 2 diabetes (70-74) and elevated blood glucose (70) are at higher 
risk of dementia and experience more rapid progression from MCI to AD (75). 
Peripheral hyperglycemia and insulin resistance are believed to promote cerebral 
glucose hypometabolism (76-79). Slight elevation of fasting blood glucose in cognitively 
normal individuals is associated with diminished glucose metabolism in brain regions 
highly affected in AD (77-79). 
Cerebral hypometabolism is believed to be one of the mechanisms involved in 
upregulated cerebral Aβ deposition seen in AD pathology (80). In a mouse model of AD, 
inducing acute hyperglycemia through intravenous flow of dextrose increased Aβ in the 
interstitial fluid of the brain (81). Late middle age adults with insulin resistance had 
increased regional cerebral Aβ burden while cognitively normal older adults with 
impaired fasting glucose also demonstrate increased regional cerebral Aβ burden (67, 
 11 
82). Because neuronal protein processing requires a steady flux of energy, 
hypometabolism elicited bioenergetic deficits likely contribute to impaired processing of 
Aβ and plaque accumulation (8). The relationship between cerebral glucose 
hypometabolism and Aβ processing may be cyclical in that downgregulated brain 
glucose metabolism could potentiate Aβ burden and further intensify cerebral 
hypometabolism (83). 
 
Sugar, Glycemic Index and Glycemic Load in AD 
 Glucose metabolism is severely downregulated in and prior to onset of AD. 
Accumulating evidence also points to a role for conditions of altered metabolic status as 
a risk factor for AD. Despite existing links of glucose metabolism with Aβ processing 
and influence of dietary intake on glucose metabolism status, very little work has been 
done to assess the relationships of sugar and highly glycemic carbohydrates with AD. 
 Dr. David Jenkins and colleagues developed the glycemic index (GI) in 1981, a 
scale that scores the postprandial glycemic response of carbohydrate containing foods 
relative to a reference of glucose or white bread (84, 85). GI scores represent the area 
under a 2-hour glucose response curve following a 12 hour fast and 50g ingestion of a 
carbohydrate containing food (85). On a scale of 0-100, foods with a GI greater than 70 
are considered high glycemic foods, while those between 56-74 are considered medium 
glycemic foods and those less than 55 are considered low glycemic foods. 
 Walter Willett first proposed glycemic load (GL) in 1997 (86). GL is intended to 
describe the anticipated glycemic effect of carbohydrate consumption using the GI and 
taking into account the quantity of carbohydrate consumed. GL is calculated as GL = 
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(GI of individual food x grams carbohydrate per serving)/100. Studies demonstrated that 
GL consumed through the day can be summed to establish a cumulative daily GL (87) 
and that the GL was predictive of the glycemic response of ingestion of a mixed 
macronutrient meal (88). 
 It is well established that diets rich in high GI foods, characterized by intake of 
processed carbohydrates and sugar, are strongly associated with impaired glucose 
metabolism, including insulin resistance and type 2 diabetes (86, 89-95). Intake of 
carbohydrates with a high GI elicits sharp postprandial spikes in blood glucose and 
requires a greater insulin demand for glucose shuttling. Diets consisting of carbohydrate 
with a high GI and GL are correlated with fasting hyperglycemia and hyperinsulinemia 
as well as decreased insulin sensitivity (96). This is important because individuals with 
type 2 diabetes are significantly more likely to develop dementia and experience more 
rapid progression once dementia begins (75). 
We must look to rodent models to evaluate the role of sugar intake in AD risk. 
Inducing acute hyperglycemia in mice through intravenous flow of dextrose increased 
Aβ in the interstitial fluid of the brain (81). This suggests that acute hyperglycemia from 
the consumption of processed carbohydrates and sugars could potentially mimic this 
effect. When fed a high sugar and high fat diet, mice develop metabolic syndrome and 
express upregulated Aβ deposition and tau phosphorylation (97). Dietary-induced 
insulin resistance in rodents through high intake of sugar or high fructose corn syrup 
resulted in elevation of Aβ burden and significant impairment of cognition (98-100). 
These studies and others suggest that acute increases in insulin and insulin signaling 
through the consumption of high glycemic foods may change Aβ levels in the brain 
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 Ketone bodies result from the mobilization of fatty acids to the liver where they 
undergo conversion from fatty acids to ketone bodies. There are three ways in which 
serum levels of ketone bodies are elevated, through 1) increased mobilization of 
endogenous fatty acids due to prolonged fasting (103), 2) adherence to a ketogenic diet 
(KD) (104), and 3) intake of ketogenic agents, such as medium-chain triglycerides 
(MCT) or exogenous ketone body substrates (105, 106). From a therapeutic standpoint, 
it is common practice to combine the ketogenic diet with intake of ketogenic agents (i.e. 
a ketogenic diet supplemented with MCT) (107). 
 Ketosis as a result of fasting and following the KD are relatively similar 
mechanistically, i.e., ketosis is the result of decreased glucose availability and increased 
mobilization of fatty acids. Ketogenic agents have different mechanisms. MCT induced 
ketogenesis is unique in that MCTs are rapidly absorbed by the enterocyte and enter 
the portal vein gaining direct access to the liver, a key distinction from short and long 
chain fatty acids which first enter the lymphatic system. MCT is also unique in that it is 
not dependent upon carnitine activation for beta-oxidation in the liver, resulting in rapid 
ketogenesis. Exogenous ketones, often in the form of ketone esters, are bound ketone 
bodies that are hydrolyzed and absorbed intact resulting in elevated serum ketone 
levels. Ketogenic agents alone acutely raise serum ketone levels until the ketone bodies 
are cleared through metabolic pathways and serum levels normalize. 
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The liver is estimated to have the capacity to synthesize 185g of ketone bodies 
per day (108). Hepatic mitochondria convert acetyl-CoA from beta-oxidized fatty acids 
to the ketone bodies acetoacetate, β-hydroxybutyrate and, to a lesser extent, acetone 
(109). Ketone bodies translocate to the mitochondria of extrahepatic tissue where they 
are retro converted to acetyl-CoA and enter aerobic respiration pathways (109). The 
brain readily uses ketones as a fuel source in prolonged fasting. The two major energy-
contributing ketones, acetoacetate and β-hydroxybutyrate, can provide up to 60% of the 
brain’s functional energy requirements (110). During periods of low levels of serum 
insulin, fatty acids are mobilized and transported to the liver where they are metabolized 
to ketone bodies that are released to the blood. Ketones transport across the blood 
brain barrier and the cerebral metabolic rate of ketones (CMRk), a measurement of 
brain ketone utilization, is highly related to plasma ketone concentration (111). High 
plasma ketone concentration influences neurons and astrocytes to increase the 
expression of monocarboxylic acid transporters, which are responsible for the transport 




 Dr. Russell Wilder at the Mayo Clinic first wrote about the ketogenic diet in 1924 
(113). Until recently, the ketogenic diet has been considered nearly exclusively in the 
realm of seizure control therapy in Epilepsy. The typical American diet differs greatly 
from the ketogenic diet in that it is typically defined by high carbohydrate consumption 
(50-65% of energy) while the ketogenic diet is very high in fat and commonly reduces 
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carbohydrate to less than 10% of energy. Through the years, the diet has taken on 
several different iterations with varying levels of ketogenic potency. Typically, the diet is 
referenced as a ratio of grams of fat to grams of carbohydrate and protein combined. 
 4:1 Ketogenic Diet. The classic ketogenic diet has long been the standard for 
ketogenic therapy in epileptic children. This version of the diet consists of 90% of 
energy as fat, 2% of energy as carbohydrate and 8% of energy as protein. 
 The 3:1 Ketogenic Diet. The 3:1 diet is very similar to the classic 4:1 ketogenic 
diet with 87% of energy from fat, 4% of energy as carbohydrate and 9% of energy as 
protein. 
 The 2:1 Ketogenic Diet. The 2:1 ketogenic diet is slightly less restrictive than its 
4:1 and 3:1 counterparts. It is characterized by 82% of energy from fat, 8% of energy 
from carbohydrate and 10% of energy as protein. 
 The 1:1 Ketogenic Diet. The 1:1 ketogenic diet is the least restrictive of the 
ketogenic ratios. This ratio consists of 70% of energy from fat, 10% of energy from 
carbohydrate and 20% of energy from protein. Many of the more liberal iterations of the 
ketogenic diet use the 1:1 ketogenic ratio as their dietary basis. 
Table 2 Classical Ketogenic Diets 
  4:1 KD 3:1 KD 2:1 KD 1:1 KD 
Fat % (g) 90% (200g) 87% (193g) 82% (182g) 70% (156g) 
Carbohydrate % (g) 2% (10g) 4% (20g) 8% (40g) 10% (50g) 
Protein % (g) 8% (40g) 9% (45g) 10% (50g) 20% (100g) 
Grams of macronutrients based off reference of 2000 
calories   
 
 MCT-Supplemented Ketogenic Diet. Based on the macronutrient distribution from 
the 1:1 ketogenic diet, this version aims to provide 30-40% of the total fat consumed as 
 16 
MCT. Due to the ketogenic nature of MCT, the MCT-supplemented ketogenic diet 
allows individuals to be more liberal with their carbohydrate and protein intake. 
Adherence to this diet has been shown to be as effective at halting seizures as the 
classic ketogenic diet and to result in similar peak ketone production (114). 
 Modified Atkins Diet. The Modified Atkins Diet (MAD), designed by physicians at 
Johns Hopkins Hospital, is a less restrictive version of the ketogenic diet (115). This 
version of the diet is primarily based on a 1:1 ketogenic ratio. In its use as an epilepsy 
treatment, the initiation of the diet limits patients to 10 g of carbohydrate per day 
gradually increasing to the 1:1 ratio over the subsequent months (116). In epilepsy, 
MAD has been shown to be more feasible than classical ketogenic diet approaches with 
very similar seizure control (117). 
 There is growing interest in the potential use of the ketogenic diet as a therapy 
outside of epilepsy. The ketogenic diet is linked to many biological pathways (i.e. fatty 
acid oxidation, oxidative stress, inflammation, etc.) suggesting that it could be and 
approach to favorably manipulate bioenergetics in several neurological diseases (118). 
 
Can Ketone Bodies Compensate for Bioenergetic Deficit in AD? 
 This review previously outlined the bioenergetic deficit caused by impaired 
glucose metabolism in AD. It has been proposed that the presence of ketone bodies 
could compensate for this deficit (119, 120). Recent studies have investigated the 
potential role for ketones and have constructed a compelling argument for this very 
concept. 
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 Castellano et al. (35) designed a study to test whether ketone metabolism 
remains intact in patients with AD. In accordance with consistent previous findings, a 
cohort of mild AD patients was shown by FDG-PET to have significantly impaired 
cerebral glucose uptake when compared to age matched healthy adults using. CMRk 
measured by PET using radioactively marked acetoacetate (C-AcAc), sans ketogenic 
intervention, was the same in both groups. 
 An additional study performed by the same group tested the hypothesis that 
increasing the availability of ketones would affect CMRk in adults (121). A 4.5:1 ratio 
liquid ketogenic diet was provided to 10 adults across the age span for 4 days. Ketosis 
was achieved by the participants with an 8-fold elevation of serum ketone levels by day 
4. CMRk was elevated to 33% of total brain energy metabolism while CMRk was 
reduced by 20%, indicating a significant switch from cerebral metabolism of glucose 
toward ketone metabolism. 
 Whether or not the CMRk response to ketone availability is induced in individuals 
with AD is still to be determined. A current study in progress suggests that AD brains 
may even exceed the CMRk response seen in healthy adults (Cunnane or Courchesne-
Loyer Abstract). 
  
Ketogenic Diet/Ketones in AD 
The potential use of brain ketone delivery as a treatment for AD was proposed in 
1989 (119). It is desirable to know if systemic ketosis could potentially serve as a 
therapeutic intervention in AD. Many reviews have proposed the concept of ketones as 
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a possible treatment in AD; however, to date, very few studies have evaluated the 
feasibility and efficacy of ketosis as an AD treatment. 
Yao et al. investigated the effect of ketosis in the female triple-transgenic AD 
mouse model. The experimental group received a diet consisting of 0.04% 2-Deoxy-D-
Glucose (2-DG) for 7 weeks while the control group received a regular chow diet (122). 
2-DG has a structural resemblance to glucose; however, 2-DG is unable to undergo 
phosphorylation, which competitively inhibits glucose metabolism and promotes 
elevation of ketone bodies. Exposure to the 2-DG diet for 7-weeks induced a significant 
increase in serum beta-hydroxybutyrate, sustained mitochondrial function and 
significantly reduced oxidative stress. An inverse correlation between beta-
hydroxybutyrate levels and brain amyloid levels was also demonstrated. 
Henderson et al. tested the clinical potential of beta-hydroxybutyrate in AD in a 
randomized, double-blind clinical trial in which 86 participants received caprylic 
triglyceride and 66 participants received a placebo (105). Caprylic triglyceride is a 
medium chain triglyceride (MCT) that is converted to ketone bodies in the liver. Two 
hours after caprylic triglyceride consumption, serum beta-hydroxybutyrate levels 
increased approximately 4-fold. By study day 90, serum levels rose from about 0.1 mM 
to 0.40 mM in the participants receiving caprylic triglyceride. On day 45 the active 
treatment group’s Alzheimer’s Disease Assessment Scale-Cognition Subscale 
(ADASCog) score improved by 0.31 points and was significantly better than the placebo 
group’s score, which worsened by 1.23 points. The treatment group’s ADASCog scores 
also improved on day 90, although the improvement was not statistically significant. 
Participants who expressed the APOE4 negative genotype receiving caprylic 
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triglyceride demonstrated significantly better ADASCog scores than the placebo group 
at 45 and 90 days with differences of 5.73 points and 4.39 points, respectively. 
Krikorian et al. randomized 23 MCI participants to either a low carbohydrate or 
high carbohydrate diet (123). Twelve participants were assigned to the low 
carbohydrate diet that limited daily carbohydrate consumption to 5-10% of total caloric 
intake while 11 participants consumed a diet that consisted of ~50% carbohydrate. At 
the end of the 6-week intervention, urine ketones rose from 0 mg/dL to 5.4 mg/dL in the 
carbohydrate restriction group. Cognition was evaluated using the paired associate 
learning test. The low carbohydrate treatment group significantly improved their 
cognition scores from baseline to 6 weeks. Furthermore, a positive correlation between 
urine ketone levels and memory test improvement was observed. The eleven 
participants who maintained a high carbohydrate diet showed no change in urine 
ketones and no cognitive improvement. 
A case study published in 2015 reported that dosing of 28.7 g of ketone ester 
three times per day effectively raised serum ketone levels and was well tolerated (106). 
Although no clinical assessment of cognition was performed, the case review reported 
that the patient exhibited improved behavior and cognition over the course of 20 
months. 
A review from 2012 compiled relevant evidence regarding ketosis and oxidative 
stress (124). Oxidative stress is believed to play a significant role in the pathogenesis of 
AD. Although the body of evidence is limited, evidence infers that, in rats, the ketogenic 
diet improves oxidative stress status by decreased ROS, upregulation of glutathione 
and potential down downregulation of key inflammatory pathways. 
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Although limited data involving the ketogenic diet or ketone therapies in AD exist, 
the current body of evidence supports the premise that these interventions are worthy of 
further investigation. While a previous study investigated carbohydrate restriction in 
MCI, at this point, it is unclear whether individuals with AD are capable of following the 
ketogenic diet or if following the diet would improve AD symptomology. Addressing 
these questions is the purpose of the research presented in the ketogenic portion of this 
dissertation. 
 
Research Questions and Gaps in Literature 
1.) How does intake of sugar and foods with a high glycemic index affect AD pathology, 
primarily Aβ accumulation? 
There has been a great effort to elucidate the mechanisms of glucose metabolism’s 
influence on brain hypometabolism and amyloid processing, yet very little literature 
connecting dietary intake to objective measures for AD risk exists. I hypothesize that 
that sugar intake and glycemic load intake is positively correlated with cerebral amyloid 
burden. 
 
2.) What is the relationship between intake of a High Glycemic Load Diet pattern and 
accumulation of Aβ? 
Study of dietary patterns in relation to various outcomes has become more common. 
Evaluation of eating patterns is a more comprehensive manner of looking at dietary 
intake than solitary nutrients. Principal components analysis was used to identify actual 
dietary patterns within our dataset. The first pattern was strongly associated with 
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glycemic load and sugar intake, therefore it was named the High Glycemic Load Diet 
pattern. I hypothesize that, like my previous hypothesis for glycemic load and sugar 
intake, the High Glycemic Load Diet pattern will positively correlate with cerebral 
amyloid load. 
 
3.) Is the MCT-supplemented ketogenic diet feasible in patients with AD? 
Although the Krikorian study investigated the feasibility of carbohydrate restriction in 
MCI, no studies have been designed to evaluate the feasibility of the ketogenic diet in 
AD. Demonstrated feasibility of KD in patients with AD would provide justification for 
evaluating efficacy of KD as a treatment option for AD patients. 
 
4.) Does following a ketogenic diet elicit cognitive benefit in patients with AD? 
While reviews and editorials have speculated that ketones may overcome 
bioenergetic deficits observed in AD, however, there are yet to be any clinical trials to 
evaluate the cognitive efficacy of KD in patients with AD. In conjunction with feasibility, 
demonstration of potential cognitive benefit of KD in patients with AD could further 
































Two studies have been considered for the purpose of answering the questions 
proposed in this dissertation. The following will address the methods from both studies. 
 
Alzheimer’s Prevention through Exercise (APEX) 
 The Alzheimer’s Prevention through Exercise (APEX) is a randomized controlled 
exercise trial intended to examine the effects of exercise on AD biomarkers and 
cognition. At screening, potential participants undergo Florbetapir F18 PET imaging to 
assess and quantify cerebral amyloid status. Eligible participants with elevated amyloid 
enroll in the APEX study. Potential participants that are non-elevated enter the 
Alzheimer’s Prevention Program study, an imaging sub-study of APEX with an 
enrollment goal of 400 cognitively normal older individuals. Data from the screening visit 
(prior to APEX intervention) were analyzed cross-sectionally including both amyloid 
elevated and non-elevated participants. 
 
Eligibility 
Prior to enrollment in APEX or APP, participants were enrolled in the KU 
Alzheimer’s Disease Center Registry. The registry is intended to develop a well-defined 
pool of recruitable individuals for AD research studies. All possible recruits were eligible 
for APP if they met the following criteria: a) age 65 or older; b) CDR of 0 (no dementia) 
(125) as assessed by a cognitive battery (126), clinical assessment and interviews with 
potential participant family members (all clinical assessments were reviewed at a 
consensus diagnosis conference); c) no clinically significant depression (Geriatric 
Depression Scale score at sub-study Visit 1 must be 5 or less); d) no clinically 
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significant anxiety (Beck Anxiety Index at sub-study Visit 1 must be 16 or less) and e) 
sedentary or underactive based on the Telephone Assessment of Physical Activity (127) 
(score of 4 or less). 
Individuals were excluded from participation of this study if they had a) clinically 
significant hepatic, renal, pulmonary, metabolic, endocrine, psychiatric or medical 
disturbances as indicated by history, which, in the opinion of the investigator, posed a 
potential safety risk to the subject; b) history of relevant severe drug allergy or 
hypersensitivity; c) received a radiopharmaceutical for imaging or therapy within the 24 
hours prior to the imaging session for this study or d) current or recent participation in 
any procedures involving radioactive agents such that the total radiation dose exposure 
to the subject in any given year would exceed the limits of annual and total dose 
commitment set forth in the US Code of Federal Regulations (CFR) Title 21 Section 
361.1. 
 
Assessment of Dietary Intake 
 At visit 1, usual dietary intake was assessed using the web-based National 
Cancer Institute Diet History Questionnaire II (DHQII) 
(https://epi.grants.cancer.gov/dhq2/) which is a semi-quantitative, 134 food item food 
frequency questionnaire. Participants were asked to report the average frequency of 
consumption and portions of food items for the previous year. Estimated nutrient data 




Florbetapir F18 PET Image Acquisition 
Florbetapir F18 PET scans were acquired on a GE Discovery ST-16 PET/CT 
scanner at visit 2. Vital signs were taken in a supine position immediately prior to 
administration of florbetapir F18. A 370 MBq bolus injection of florbetapir F 18 was 
administered and two PET brain frames of 5 minutes in duration were acquired 
continuously approximately 50-minutes post-injection. PET acquisitions were 
reconstructed immediately after scan completion. If any motion was detected, a second 
continuous scan was acquired. Subjects were observed continuously for signs of 
adverse events or serious adverse events. 
 
Assessment of Cerebral Amyloid Burden 
Florbetapir F18 PET images were analyzed both qualitatively and quantitatively. 
Qualitative analysis was performed by 3 trained raters (either a radiologist or nuclear 
medicine physician) blinded to the subject diagnosis and reported images as either 
“elevated” Aβ levels (AD-like) or “not-elevated” Aβ levels (not AD-like). The final 
determination whether images were elevated or non-elevated was determined by 
majority (i.e., ≥2 raters in agreement). Quantitative analysis was processed using 
MIMneuro (MIM Software Inc., United States) software to measure mean standard 
uptake values (SUV) for target areas including the anterior cingulate, posterior 
cingulate, precuneus, inferior medial frontal, lateral temporal and superior parietal cortex 
and a reference region consisting of the cerebellum using a proprietary algorithm. 
Standard uptake value ratios (SUVR) for each cortical target area was calculated 




All participants completed a standard battery of neuropsychological tests that 
included the Mini-Mental State Exam (MMSE), the Wechsler Adult Intelligence Scale – 
Revised (WAIS-R) Digit Symbol, Trail Making Test A, Trail Making Test B, Category 
Fluency (animals and vegetables), the Stroop Color-Word Interference Test, the WAIS-
R Block Design and the total free recall score from the Free and Cued Selective Recall 
Test (126). 
 
Ketogenic Diet Retention and Feasibility Trial 
Eligibility 
Individuals were eligible for this study if they 1) met the criteria for MCI Due to 
AD, Mild AD or Moderate AD; 2) had a study partner; 3) had a BMI greater than 21 
kg/m2; 4) had serum electrolytes, liver function tests (LFTs) and cholesterol levels within 
normal limits and 5) spoke English as a primary language. Individuals were ineligible if 
they reported any of the following criteria: if they 1) did not have a study partner to 
assist in implementation and maintenance of the ketogenic diet; 2) consumed greater 
than 2 drinks of alcohol per day; 3) reported serious medical risk such as insulin-
dependent diabetes, cancer, or recent cardiac event (i.e. heart attack, angioplasty, etc.) 




 Participants were weighed on a calibrated scale in light clothing without shoes 
and weight recorded to the nearest 0.1 lb. Height was measured using a stadiometer 
without shoes and recorded to the nearest 0.1 cm. All anthropometric data were 




 Dual-energy x-ray absorptiometry (DEXA) scans were performed by the Exercise 
Physiology Lab located in the CTSU prior to diet initiation and at the end of the diet 
intervention. Total body tissue quantitation was obtained via a total body scan, which 
provided output for 3 tissue compartments; lean tissue, fatty tissue and bone. Lunar 
Encore software (Version 13.6) used to quantify tissue of each compartment. 
 
Blood Collection and Assays 
Fasting serum samples were collected and processed by nurses in the CTSU. 
Laboratory values collected just before the start of the intervention and at its completion 
included serum electrolytes, including calcium, chloride, magnesium, phosphorus, 
potassium and sodium; liver function tests (LFTs), including AST, ALT and ALP; renal 
labs, including BUN and creatinine; and a full lipid panel, including total cholesterol, 
LDL, HDL and triglycerides. Plasma insulin levels and β-hydroxybutyrate were collected 
at one-month intervals. KU Medical Center Clinical Laboratory analyzed all assays with 
respective ELISA kits. 
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Plasma insulin and glucose was measured at baseline and at the end of the diet 
intervention. We calculated Homeostatic Model Assessment for Insulin Resistance 
(HOMA-IR) values for each participant. Whole body insulin sensitivity (HOMA2-IR) was 
calculated using HOMA2 Calculator (v. 2.2.3; University of Oxford, United Kingdom). 
 
Electrocardiogram (ECG) 
 Electrocardiography was recorded at Baseline, Month 1 and Month 2 of the 
dietary intervention. We monitored for any changes in Q-wave activity. Nurses in the 
CTSU obtain all electrocardiography and the recordings were analyzed by the study 
physicians and trained staff. 
Cognitive Assessment 
Cognitive performance was assessed using the cursory mini-mental state exam 
(MMSE) and the more detailed AD Assessment Scale cognitive subscale (ADASCog). 
The MMSE is a 30-point survey designed to measure participant orientation, immediate 
recall, attention and calculation, recall and various aspects of language (128). The 
ADASCog consists of 11 tasks and measures the disturbances of memory, language, 
praxis, attention and other cognitive abilities that are often referred to as the core 
symptoms of AD (129). Experienced KU ADC staff conducted cognitive testing at three 




Assessment of Ketones 
Participants recorded urinary acetoacetate results using Ketostix (Bayer, 
Germany) each evening. The observed color changes indicated the presence of no (~0 
mg/dL), trace (~5 mg/dL), small (~15 mg/dL), moderate (~40 mg/dL), high (~80 mg/dL), 
or very high (~160 mg/dL) acetoacetate. Participants recorded urinary ketone results in 
a diary provided by study personnel. 
 
Dietary Intake 
 Dietary intake was assessed by 3-day food records. Participants recorded 3 
consecutive days of intake; 2 weekdays and one weekend day. Baseline food records 
were completed prior to starting the ketogenic diet in order to estimate normal dietary 
intake. Food records completed at the end of the and second months reflected dietary 
intake while consuming the ketogenic diet. Data from the 3-day food records were 
entered into the Nutrition Data System for Research (NDSR, v. 2016) software. 
 
Statistical Analyses 
 Analyses were performed using R (v. 3.3.2; R Foundation, Vienna, Austria). All 
statistical analyses were two-sided with statistical significance set at p≤0.05. 
 
Dietary Glycemic Measures and Cerebral Amyloid Burden 
Linear regression models were used to investigate the relationships between 
dietary glycemic measures (carbohydrate, sugar and glycemic load) and regional 
cerebral amyloid burden (SUVR) in 126 cognitively normal older adults. Residual 
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analyses were performed on all dependent variables to assess applicability of linear 
regression and normality was assessed using the Shapiro-Wilk test for normality. 
Dependent data with non-normally distributed residuals were log transformed. All 
analyses were controlled for age and gender. 
 
High Glycemic Load Dietary Pattern and Cerebral Amyloid Burden 
 Dietary patterns were produced using principal components analysis (PCA). The 
NDSR output consolidates a possible 7,752 foods consumed by participants into 32 
food variables of the My Pyramid Equivalents Database 2.0 (MPED 2.0) (130). MPED 
2.0 variables were included in the PCA correlation matrix and rotated with the varimax 
rotation method. The first rotated factor, describing 13.7% of the variability in the data, 
was retained from the factor analysis. This factor (dietary pattern) was regressed 
against energy, fat, protein, carbohydrate and glycemic load. The dietary pattern was 
named the High Glycemic Load Dietary pattern because it was associated with 
carbohydrate, sugar and most correlated with glycemic load. 
 The relationships between the High Glycemic Load Dietary pattern with global 
and regional amyloid burden were assessed using linear regression. Analyses were 
controlled for age, gender, BMI and education level. 
 
Dietary Measures/Patterns and Cognition 
Linear regression models were used to investigate the relationships between 
dietary glycemic measures (carbohydrate, sugar and glycemic load) and the High 
Glycemic Load Dietary pattern with individual cognitive tests from the cognitive battery 
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and a computed global cognitive score. Residual analyses were performed on all 
dependent variables to assess applicability of linear regression and normality was 
assessed using the Shapiro-Wilk test for normality. Dependent data with non-normally 
distributed residuals were log transformed. Analyses were controlled for age, gender, 
BMI and education level. 
 
MCT-KD Feasibility 
 Feasibility of the ketogenic diet was determined, in large part, by descriptive 
statistics. Normality of the dependent variables was assessed through Q-Q visualization 
of residuals models. Paired t-tests were utilized to analyze differences in dietary 
macronutrient intake prior to and during diet intervention. Changes in serum ketone 
status during the dietary intervention were analyzed using the non-parametric Friedman 
test with Conover post-hoc analyses. 
 
Changes in Cognition 
 Pre and post dietary intervention cognition scores were analyzed using repeated 
measures ANOVA. Assumptions for ANOVA were evaluated by visualization of Q-Q 














Chapter Three: High Glycemic Diet is Associated with Cerebral Amyloid Burden 

















Objective: Examine the relationship of dietary glycemic measures with cerebral amyloid 
burden and cognitive performance in cognitively normal older adults. 
Methods: We performed cross-sectional analyses of dietary glycemic measures (high 
glycemic load diet pattern [HGLDiet], sugar intake, carbohydrate intake and glycemic 
load) with cerebral amyloid burden (measured by florbetapir F-18 PET) and cognitive 
performance in 128 cognitively normal older adults screened for the University of 
Kansas Alzheimer’s Prevention through Exercise trial.  
Results: Amyloid was elevated in 25.4% (n=32) of subjects. Adherence to an HGLDiet 
pattern was significantly higher in elevated subjects (p=0.015). The HGLDiet pattern 
was positively associated with amyloid burden both globally and in all regions of interest 
independent of age, gender, and BMI (all p-values ≤ 0.001). Individual dietary glycemic 
measures (sugar intake, carbohydrate intake and glycemic load) were also positively 
associated with global amyloid load and nearly all region regions of interest independent 
of age, gender and BMI (p-values ≤ 0.05). Cognitive performance was associated only 
with daily sugar intake, with higher sugar consumption associated with poorer global 
cognitive performance (Global Composite and Mini-Mental State Exam) and 
performance on subtests of Digit Symbol, Trailmaking B, and Block Design controlling 
for age, gender, and education. 
Conclusions: A high glycemic diet is associated with greater cerebral amyloid burden, 





Alzheimer’s disease (AD) is the most common form of dementia, affecting more 
than 1 in 8 Americans over the age of 65 and costing the American economy over $385 
billion per year (2). AD prevalence is projected to increase to nearly 14 million by the 
year 2050 (2). As disease modifying therapies that slow decline in symptomatic patients 
are currently lacking, an interest in identifying approaches to prevent or delay AD onset 
has emerged (131). It is believed that lifestyle behaviors, including diet, could modify AD 
risk and that diet interventions could be used to reduce AD risk (132). 
Recent studies demonstrate impaired glucose metabolism and peripheral 
hyperglycemia associate with AD risk. For instance, individuals with type 2 diabetes (71, 
72) and elevated blood glucose (70) are at higher risk of dementia and experience more 
rapid progression from mild cognitive impairment (MCI) to AD (75). Peripheral 
hyperglycemia and insulin resistance are also believed to promote cerebral glucose 
hypometabolism as evidenced by PET imaging studies (76-79). Cerebral 
hypometabolism itself has been implicated in cerebral amyloid-beta (Aβ) deposition, 
which manifests in the form of the extracellular plaques (80). Further, a recent study 
demonstrated impaired fasting glucose associates with increased regional cerebral Aβ 
burden in a cohort of cognitively normal adults (67). 
Postprandial glycemia and insulin secretion are highly affected by the amount 
and type of carbohydrate consumed in the diet (133). Dietary intake of a high glycemic 
load, which can be characterized by a high intake of processed carbohydrate and sugar, 
elicits sharp spikes in peripheral glucose and insulin secretion. Diets with high in 
glycemic load have been strongly linked to impaired glucose metabolism and increased 
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risk of type 2 diabetes (96), which may also implicate diet as a modifiable behavioral 
factor that affects amyloid aggregation. Assessment of the association between dietary 
components and patterns known to affect glucose metabolism and Aβ deposition could 
help further elucidate their relationship with AD risk. 
Despite recognized relationships between glucose metabolism and Aβ 
processing (67), as well as an appreciation for the fact that diet affects glucose 
metabolism (96), potential correlations between high dietary glycemic intake and 
cerebral amyloid burden remain relatively unexplored. In this cross-sectional study, we 
examined whether a high glycemic diet – as measured by a survey-based assessment 
of adherence to a High Glycemic Load diet pattern and estimates of daily carbohydrate 
intake, sugar intake, and glycemic load – associates with global and regional cerebral 




We examined cross-sectional data collected from individuals screened for the 
University of Kansas Alzheimer’s Prevention through Exercise [APEX] trial to assess the 
association of dietary glycemic measures with regional cerebral amyloid burden. The 
APEX study is a randomized trial examining the effects of aerobic exercise on AD 
biomarkers (amyloid burden and MRI volumetrics) and cognitive decline in cognitively 
normal older adults 65 years and older (NCT02000583) conducted at the University of 
Kansas Alzheimer’s Disease Center. Only screening or baseline data (i.e., prior to any 
intervention) was used for these analyses.  
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Subjects 
Data were available on 128 cognitively normal, sedentary participants age 65 
and older that screened for the University of Kansas Alzheimer’s Prevention through 
Exercise (APEX) study. Participants were assessed by a trained clinician and performed 
a battery of cognitive tests (126) to exclude the presence of mild cognitive impairment or 
dementia syndromes. The trained clinician interviewed the participant and their study 
partner (usually a spouse or child) to assess for evidence of clinical decline and to 
complete a Clinical Dementia Rating (CDR) (125). Clinical and cognitive data were 
reviewed at a consensus diagnosis conference and eligible participants were CDR 0 (no 
dementia) and also without clinically significant deficits in their cognitive test 
performance. Participants were sedentary or underactive based on the Telephone 
Assessment of Physical Activity (127) (score of 4 or less) and willing to participate in a 
52 week exercise intervention. Exclusion criteria for the APEX study included clinically 
significant depression or anxiety, insulin-dependent diabetes, uncontrolled 
hypertension, or recent history of major neuropsychiatric, musculoskeletal, or 
cardiorespiratory impairment in the last 2 years. The study protocol was approved by 
the Institutional Review Board at the University of Kansas Medical Center. Informed 
consent was obtained from all study participants according to institutional guidelines. 
 
Dietary Intake Assessment 
Usual dietary intake was assessed using the web-based National Cancer 
Institute Diet History Questionnaire II (DHQII) (https://epi.grants.cancer.gov/dhq2/) 
which is a semi-quantitative, 134 food item food frequency questionnaire. Participants 
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were asked to report the average frequency of consumption and portions of food items 
for the previous year. Estimated nutrient data were quantified using the NCI Diet*Calc 
software (https://epi.grants.cancer.gov/dhq2/dietcalc/). 
 
Dietary Glycemic Measures 
We examined four dietary glycemic measures derived from the DHQII: daily 
intake of carbohydrate, sugar, glycemic load and adherence to a high glycemic load diet 
pattern. Three of these measures represent output variables from the DHQII (daily 
intake of carbohydrate, sugar and glycemic load) while adherence to a high glycemic 
load diet pattern was determined using principal components analysis (PCA).  
PCA was used to identify adherence to a glycemic load dietary pattern. Food 
variables were established using My Pyramid Equivalents Database 2.0 (MPED 2.0) 
(130) which includes 32 food groups derived from 7,752 different foods. All food 
variables were entered into the factor analysis and rotated with the varimax rotation 
method to maximize interpretability of the data. Factor loading scores were computed 
for each individual food group. Higher factor loading values represent stronger 
correlations between each individual food group and its contribution to a specific dietary 
pattern. The first rotated factor from the PCA, which explained 13.7% of the total data 
variance, exhibited high loading factors on food groups that are associated with high 
glycemic load; it was, therefore, labeled the High Glycemic Load Diet pattern (HGLDiet 
pattern). Individual factor regression scores, which represent a quantitative value of 
individual adherence to a specific dietary pattern, were calculated for each study 
participant by summing the intake of each food group multiplied by its factor loading 
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value from the HGLDiet pattern component. Linear regression was used to evaluate the 
association between the HGLDiet pattern factor scores and daily glycemic load scores. 
The HGLDiet pattern was strongly correlated with daily glycemic load (r2=0.58, p < 
0.001, Figure 1) and daily sugar intake (r2=0.27, p < 0.001), which rationalized the 
designation of this dietary pattern. 
Rotated factor loadings for the individual food groups and the HGLDiet pattern 
are shown in Figure 2. The HGLDiet pattern was characterized by high intake of high 
glycemic load foods such as total grains, refined grains, potatoes, starchy vegetables 
and added sugars. Whole grains, lean and fatty meat and discretionary fats also loaded 















Figure 1 The relationship between Glycemic Load and HGLDiet pattern 
 
The HGLDiet pattern was highly correlated with glycemic load intake (r2=0.58, p < 













Figure 2 Rotated factor loadings for the High Glycemic Load Diet pattern 
 
Factor loading coefficients are represented as the bars (10x). Greater intake of foods 
that have high positive loading coefficients results in higher HGLDiet pattern adherence 
scores. Greater intake of foods with low or negative loading coefficients results in 




 Body weight and height were measured for all subjects. Body weight was 
measured with a calibrated scale (± 0.1 kg). Height was measured with a wall-mounted 





















































Assessment of Cerebral Amyloid Burden 
PET images were obtained on a GE Discovery ST-16 PET/CT scanner after 
administration of intravenous florbetapir F-18 (370 MBq). Two PET brain frames of five 
minutes in duration were acquired continuously approximately 50 minutes post-injection. 
Frames were then summed and attenuation corrected prior to interpretation. MIMneuro 
software (MiM Software Inc, Cleveland, OH) quantitatively normalized the amyloid-β 
PET image to the entire cerebellum to calculate the Standard Uptake Value Ratio 
(SUVR) for six regions of interest (ROIs): anterior cingulate, posterior cingulate, 
precuneus, inferior medial frontal, lateral temporal and superior parietal cortex using a 
proprietary algorithm. The mean of these 6 ROIs was calculated as the global SUVR. 
Three trained raters reviewed the visual images, the quantitative SUVR ROI data and 
MIMneuro-generated cortical projections of amyloid burden (z-scores comparing the 
SUVRs to an SUVR map of 74 individuals (48 males, 26 females) between the ages of 
18-50) to assess the scans as “elevated” or “non-elevated”. The final determination of 
elevated or non-elevated was determined by majority (i.e., ≥2 raters in agreement). 
 
Neuropsychological Testing 
 All participants completed a standard battery of neuropsychological tests that 
included the Mini-Mental State Exam (MMSE), the Wechsler Adult Intelligence Scale – 
Revised (WAIS-R) Digit Symbol, Trail Making Test A, Trail Making Test B, Category 
Fluency (animals and vegetables), the Stroop Color-Word Interference Test, the WAIS-
R Block Design and the total free recall score from the Free and Cued Selective Recall 
Test (126). Each neuropsychometric test score was converted to a z-score by 
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subtracting the study population mean from each individual test score and dividing by 
the study population standard deviation. Higher scores on the Trail Making Test A and 
Trail Making Test B indicate greater cognition impairment, thus z-scores for these tests 
were multiplied by -1 so that negative scores reflect greater impairment of cognition. A 
global cognition z-score was established by calculating the mean of the combined 
cognitive z-scores. 
 
Statistical Analyses  
The primary focus of this study was to investigate the relationship between 
regional and global cerebral amyloid burden (SUVR) and dietary glycemic measures: 
HGLDiet pattern adherence, carbohydrate intake, sugar intake and glycemic load. All 
continuous variables were expressed as mean daily intake ± SD. Differences between 
the elevated and non-elevated groups were assessed using one-way ANCOVA. Linear 
regression models were used to investigate the relationships between the continuous 
variables with regional cerebral amyloid burden (SUVR). For all dependent variables, 
residual analyses were performed to assess applicability of linear regression and 
normality was assessed using the Shapiro-Wilk test for normality. Residual normality 
issues were discovered, thus, we identified outliers using a modified z-score method 
(134) removing cases above a threshold of 3.5. Two cases were excluded due to very 
high SUVR values which resolved residual normality issues without affecting statistical 
conclusions. Dependent data with non-normally distributed residuals were log 
transformed. All analyses were controlled for age and gender. Cognitive analyses were 
further controlled by education level and analysis of relationships between dietary 
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components and cerebral amyloid burden were further controlled by education level and 
BMI. Energy intake and oral diabetes medications were considered as regression 
covariates but had no effect on statistical outcomes. Statistical analyses were 
performed using R (v. 3.3.1; R Foundation, Vienna, Austria). Statistical significance was 
set at p < 0.05. 
 
RESULTS 
Data from 126 cognitively normal participants ranging in age from 65-90 years 
(71.6 ± 5.2 years) were included. Amyloid scans were interpreted as elevated in 25.4% 
(n=32) of the participants, in line with the expected prevalence of elevated cerebral 
amyloid in cognitively normal older adults (135). Amyloid burden, anthropometric, 
neuropsychometric, dietary intake and cerebral amyloid characteristics are presented in 
Table 1. 
We first examined whether there were differences in dietary glycemic measures 
across amyloid elevated and non-elevated groups (Table 3). Controlling for age and 
gender, the elevated amyloid group had significantly higher adherence to the HGLDiet 
pattern (p=0.015) compared to the non-elevated group with a trend for higher daily 
sugar intake in those with elevated amyloid (p=0.065). There were no differences 











Table 3 Participant Characteristics 







Age, y 71.3 ± 5.1 72.5 ± 4.6 71.0 ± 5.2 0.148 
Gender (Female/Male) 83/43 19/13 64/30 0.495 
     % Female / % Male 66% / 34% 59% / 41% 68% / 32% - 
BMI, kg/m2 28.9 ± 4.8 28.4 ± 4.2 29.0 ± 5.0 0.507 
Diagnosed Diabetes 16 (12.7%) 6 (18.8%) 10 (10.6%) 0.377 
     Taking Oral DM Meds 15 (11.9%) 5 (15.6%) 10 (10.6%) 0.663 
Education (years) 16.5 ± 2.6 16.4 ± 3.1 16.6 ± 2.4 0.780 
Dietary Intake1     
Energy, kcal 1584.7 ± 673.4 1697.7 ± 757.8 1546.5 ± 642.1 0.352 
Fat, g 65.5 ± 31.1 68.0 ± 31.1 64.7 ± 31.2 0.669 
Protein, g 65.1 ± 32.0 68.6 ± 29.0 63.9 ± 33.1 0.561 
Dietary Glycemic Measures1     
Carbohydrate, g 184.4 ± 84.7 207.8 ± 111.8 176.4 ± 72.3 0.106 
Sugar, g 86.1 ± 49.2 101.6 ± 64.1 80.8 ± 42.0 0.065 
Glycemic Load 95.5 ± 47.0 106.0 ± 57.5 92.0 ± 42.6 0.202 
HGLDiet Pattern 0.09 ± 1.03 0.48 ± 1.1 -0.05 ± 1.0 0.015* 
Cognition Scores     
MMSE 29.0 ± 1.4 29.0 ± 1.0 28.9 ± 1.5 0.937 
WAIS – R Digit Symbol 50.7 ± 10.0 48.7 ± 9.5 51.4 ± 10.2 0.179 
Trail Making Test A 29.1 ± 9.7 30.7 ± 9.5 28.6 ± 9.8 0.301 
Trail Making Test B 78.6 ± 37.5 77.7 ± 25.0 78.9 ± 41.1 0.878 
Category Fluency 38.9 ± 8.3 38.2 ± 7.9 39.2 ± 8.4 0.542 
Block Design 36.6 ± 10.8 35.3 ± 9.9 37.1 ± 11.1 0.410 
Stroop 219.1 ± 31.6 215.5 ± 31.9 220.4 ± 31.6 0.453 
SRT – Free Total 30.6 ± 5.2 29.0 ± 5.3 31.1 ± 5.0 0.050* 
SUVR2     
Global 1.07 ± 0.16 1.29 ± 0.16 0.99 ± 0.06 <0.001* 
Anterior Cingulate Gyrus 1.15 ± 0.20 1.42 ± 0.20 1.05 ± 0.08 <0.001* 
Inferior Medial Frontal Gyrus 1.00 ± 0.17 1.24 ± 0.17 0.92 ± 0.06 <0.001* 
Lateral Temporal Lobe 1.09 ± 0.16 1.29 ± 0.17 1.02 ± 0.08 <0.001* 
Posterior Cingulate Gyrus 1.05 ± 0.15 1.23 ± 0.16 0.99 ± 0.08 <0.001* 
Precuneus 1.11 ± 0.21 1.39 ± 0.22 1.02 ± 0.08 <0.001* 
Superior Parietal Lobule 1.01 ± 0.15 1.18 ± 0.16 0.95 ± 0.09 <0.001* 
Abbreviations: BMI, body mass index; HGLDiet Pattern, High Glycemic Load Diet pattern; 
MMSE, Mini-Mental State Exam; WAIS – R, Wechsler Adult Intelligence Scale – Revised; 
Stroop, Stroop Color-Word Interference Test; SRT, Selective Reminding Test; SUVR, standard 
uptake value ratio 
Values are mean ± standard deviation 
Adjusted for Age and Gender 
1Derived from food frequency questionnaire 
2Derived by florbetapir F-18 PET imaging 
*Significant difference between groups (p ≤ 0.05) 
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We next examined the relationship of dietary glycemic measures with regional 
and global measures of cerebral amyloid burden (SUVR) in the overall group using 
linear regression controlling for age, gender, education level and BMI. All four measures 
of glycemic intake were positively associated with global and regional measures of 
cerebral amyloid load (Table 4). Figure 3 demonstrates the relationship of adherence to 
the HGLDiet pattern with global cerebral amyloid levels. Figure 4 illustrates the 
relationship between the HGLDiet pattern and regional cerebral amyloid using voxel-
based morphometry regression analyses. 
 
Table 4 Relationship of glycemic dietary intake measures with global and regional 









Global 0.36*** 0.21* 0.22* 0.24* 
Anterior Cingulate Gyrus 0.38*** 0.20* 0.23* 0.25** 
Inferior Medial Frontal Gyrus 0.33*** 0.17 0.16 0.18 
Lateral Temporal Lobe 0.34*** 0.22* 0.22* 0.24* 
Posterior Cingulate Gyrus 0.31*** 0.17 0.18* 0.21* 
Precuneus 0.32*** 0.22* 0.21* 0.24* 
Superior Parietal Lobule 0.30*** 0.19* 0.20* 0.21* 
Values are the estimated standard deviation change in cerebral amyloid burden (SUVR) 
per 1 standard deviation change in the respective dietary glycemic measure 
(standardized coefficients) after controlling for age, gender, education level and BMI. 














Figure 3 Association of High Glycemic Load Diet pattern adherence with global cerebral 
amyloid burden. 
 
The correlation of HGLDiet pattern adherence scores with global amyloid burden. 
HGLDiet pattern adherence explained 12% of the variability in global cerebral amyloid 
burden (r2=0.12, p ≤ 0.001). HGLDiet pattern adherence was also significantly 
correlated with amyloid burden in all regions of interest. 
 
 
Figure 4 Visualization of the relationship between High Glycemic Load Diet pattern 
adherence and cerebral amyloid burden. 
 
The High Glycemic Load Diet pattern (HGLDiet pattern) measure was regressed 
against Standardized Uptake Value Ratios for all participants. Standardized beta values 
are projected on the MNI152 anatomical template, with warmer colors representing 
regions of greater association with HGLD. 
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We also examined how dietary glycemic measures related to cognitive 
performance. Cognitive analyses were controlled for age, gender and education level. 
Daily sugar intake negatively correlated with global cognition and cognitive performance 
on several individual neuropsychometric tests (Table 5) including MMSE, Trail Making 
Test B, WAIS-R Digit Symbol, and Block Design. No other dietary measures exhibited 
relationships with neuropsychometric test scores. 
 
Table 5 Relationship of glycemic dietary intake measures with cognitive performance. 







Global -0.01 -0.26** -0.15 -0.16 
MMSE -0.07 -0.18* -0.16 -0.11 
WAIS-R Digit Symbol 0.07 -0.23* -0.13 -0.13 
Trail Making Test A1 0.02 -0.15 -0.07 -0.08 
Trail Making Test B1 0.02 -0.29** -0.16 -0.17 
Category Fluency -0.11 -0.17 -0.15 -0.15 
Stroop 0.05 -0.01 0.04 0.03 
Block Design 0.06 -0.20* -0.11 -0.13 
SRT – Free -0.04 -0.15 -0.06 -0.12 
Abbreviations: MMSE, Mini-Mental State Exam; WAIS – R, Wechsler Adult Intelligence 
Scale – Revised; Stroop, Stroop Color-Word Interference Test; SRT, Selective 
Reminding Test 
Values are the estimated standard deviation change in cognitive performance per 1 
standard deviation change in the respective dietary glycemic measure (standardized 
coefficients) after controlling for age, gender and education level.  
1For consistency with other measures, we multiplied z-scores for Trail Making Test A 
and B so that negative scores reflect cognitive decline 




The current study provides evidence that a high glycemic diet is associated with 
increased global and regional cerebral amyloid burden in cognitively normal older 
adults. We estimated 4 different dietary glycemic measures derived from the DHQII food 
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frequency questionnaire – daily intake of sugar, carbohydrate, glycemic load and 
adherence to a PCA-derived dietary pattern characterized by intake of highly glycemic 
foods – and found strong relationships with cerebral amyloid load for each measure. A 
modest negative association was found between sugar intake and cognitive 
performance but no other dietary glycemic measures. These data suggest that diet may 
be a modifiable risk factor that may influence cerebral amyloid deposition, providing 
additional evidence linking glucose metabolism with AD pathophysiology. 
Our data add to the growing body of evidence linking glucose metabolism with 
chronic disease. For instance, high carbohydrate intake and glycemic load have been 
linked with increased risk of insulin resistance, type 2 diabetes, coronary artery disease, 
stroke, and multiple cancers (96, 136, 137). Our data extend this evidence by linking 
dietary glycemic measures directly with a primary AD biomarker in cognitively normal 
older adults. Individuals with cerebral amyloid plaques in the absence of cognitive 
symptoms are at higher risk of cognitive decline (138-140), brain atrophy (69, 141), and 
progression to AD (142), although not all amyloid-positive individuals will develop 
dementia. Currently, precise estimates of the magnitude and timeframe for future risk of 
dementia are not available on an individual basis although imaging and pathological 
studies suggest plaques may accumulate up to 10 to 15 years prior to the onset of 
clinically recognized dementia (143). 
To date only limited data address the relationship between nutrition and cerebral 
amyloid. A prior longitudinal imaging initiative demonstrated that nutrient intake patterns 
related to vitamin B12, vitamin D, zinc, and omega 3 fatty acid consumption associated 
with less amyloid deposition (65, 66). Another study found an inverse relationship 
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between serum docosahexanoic acid (DHA), an omega-3 fatty acid found abundantly in 
fatty fish, and cerebral amyloid burden in older adults with normal cognition and MCI 
(68). In addition to these amyloid findings, higher intake of sugary beverages is 
associated with decreased brain volume and poorer episodic memory performance 
(144). We believe our study extends these observations by being the first to link amyloid 
deposition with dietary glycemic measures. Our finding that a high glycemic diet 
associates with with greater amyloid deposition is consistent with our prior work on a 
subset of the current cohort that found impaired fasting glycemia associates with 
increased amyloid burden in highly metabolic regions of the brain in cognitively normal 
older adults (67).  
It is well established that diets with greater intake of sugar, high glycemic index 
foods, and overall carbohydrate are linked to impaired glucose metabolism, including 
insulin resistance and type 2 diabetes (96), both risk factors for AD and cognitive 
decline (71, 72). Emerging evidence indicates that glucose and insulin status may 
influence the modulation of cerebral amyloid accumulation (80) and that elevated 
glucose may evoke a state of decreased metabolism in the brain (76-79). Protein 
homeostasis requires a steady flux of energy; bioenergetic perturbations that arise due 
to elevated glycemia and insulin resistance may potentially contribute to altered amyloid 
precursor protein or beta amyloid processing (8). Relevant to this point, an AD mouse 
model study in which acute hyperglycemia was induced through the intravenous flow of 
dextrose increased amyloid levels in the brain interstitial fluid compartment (81). Acute 
hyperglycemia from the consumption of processed carbohydrates and sugars could 
potentially mimic this effect. 
 50 
To further validate our findings, we also looked for possible relationships 
between dietary glycemic measures and cognitive performance. While 3 of the dietary 
glycemic measures did not associate with cognitive performance, higher sugar intake 
was found to inversely correlate with global cognitive performance (as measured by a 
global composite measure and the MMSE) and with individual tests in our battery (Digit 
Symbol, Trailmaking B and Block Design). Prior studies have demonstrated detrimental 
cognitive effects of high sugar and high glycemic index feedings in human and animal 
studies. Adults with type 2 diabetes fed a meal of high glycemic index/high sugar foods 
exhibited poorer acute cognitive performance (145) and cognition changes have also 
been observed in rats fed high sucrose and high-fructose corn syrup diets (98, 99, 146). 
While cognitive changes are believed to be induced by poor glycemic control, it is 
unclear as to why cognitive performance in this study was only related to sugar intake 
and not other dietary glycemic measures.  
Our study has several strengths. It featured a sample size of over 125 well-
screened, cognitively normal older adults that underwent amyloid PET imaging. The 
inclusion of only underactive or sedentary individuals controlled for any potential 
differences in physical activity and is relevant considering the majority of older adults 
are sedentary more than 8.5 hours of the day (147). An additional strength of this study 
was the input of MPED 2.0 variables into PCA analysis to identify and characterize the 
HGLDiet pattern. MPED 2.0 translates dietary intake into quantitative food group 
variables, effectively reducing the number of dietary variables to consider for analysis 
and collinearity of foods with their corresponding nutrients. Using PCA in this study 
allowed us to identify dietary patterns existing within the data collected, describe 
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interpersonal dietary intake differences and conduct a more comprehensive analysis of 
dietary intake than solely that of solitary nutrients (148). Finally, showing a modifiable 
behavior, diet, influences an AD biomarker could have strong preclinical applications. 
There were also limitations that should be considered. Cross-sectional studies 
are not designed to establish causal relationships. Food frequency questionnaires are 
demonstrated to be accurate yet are potentially subject to underreport or over report of 
some nutrients by individuals. The DHQII estimates dietary intake over the past year, 
leaving some question of chronic intake over the course of the subjects’ lifetime. 
Additionally, it is possible that amyloid status, converse to our interpretation, influences 
dietary intake. 
In conclusion, future studies are needed to further investigate the impact of 
carbohydrate intake on cerebral amyloid processing. Nevertheless, these findings in 
cognitively normal older adults suggest that dietary intake may influence amyloid 
accumulation prior to AD symptomology. Although the clinical relevance of amyloid 
burden in older adults is not precisely defined, the presence of brain amyloid 
aggregations does imply an elevated risk of future symptomatic dementia. 
Understanding the mechanisms through which dietary intake influences brain health 
and beta amyloid accumulation could have public health implications and suggest 













Chapter Four: Feasibility and Efficacy of a Medium Chain Triglyceride 

















Background: Cerebral glucose metabolism is reduced in patients with Alzheimer’s 
disease (AD). An alternative substrate, ketones, crosses the blood brain barrier and can 
be utilized for brain metabolism. It is unknown whether the ketogenic diet (high fat, low 
carbohydrate) is feasible or beneficial for patients with AD. The objective of this study 
was to assess feasibility of a 3-month medium chain triglyceride supplemented 
ketogenic diet (MCT-KD) in AD patients and generate preliminary efficacy data. 
Methods: Fifteen participants with a diagnosis of Alzheimer’s disease were recruited to 
a single-arm clinical trial where they consumed the MCT-KD for 3 months. At month 3, 
participants terminated the MCT-KD and resumed a normal diet for a 1-month washout 
period. Ketone generation was monitored through daily checking of urinary ketone 
status by the participant and monthly serum β-hydroxybutyrate assessment. Dietary 
intake was collected through baseline and monthly 3-day food records. Cognition was 
measured through administration of the mini mental state exam and the Alzheimer’s 
Disease Assessment Scale-cognitive subscale at baseline, after 3 months of the dietary 
intervention and after the 1-month washout period. 
Results: The MCT-KD was feasible in individuals with AD as 10 of the 15 participants 
produced urinary and serum ketones during the 3-month intervention. Urinary 
acetoacetate was detected an average of 54.5 days (60.6%) of the intervention in study 
completers. Serum β-hydroxybutyrate was significantly elevated from baseline at all 3 
monthly time points during the diet intervention (p≤0.001 for each). Improvements in 
ADAS-cog scores were observed from baseline to month 3 (4.1-point mean 
improvement, p=0.02) and improvements diminished after the 1-month washout. 
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Conclusion: Data from this pilot study demonstrated that a 3-month MCT-KD is 
























 It is estimated that cerebral metabolism accounts for 20% or greater of total body 
metabolism, thus the brain requires a substantial supply of energy (28, 29). Energetic 
demands of the brain are typically met by circulating glucose derived from 
carbohydrates consumed in the diet, which are quite plentiful in the common Western 
diet (30). Individuals with Alzheimer’s disease have consistently demonstrated 
reductions in cerebral glucose utilization, potentially reaching regional deficit of up to 
33% when compared to age matched adults with normal cognition (26, 34, 35). 
Alternatively, when available, the brain uses a secondary energy substrate, ketones 
(33). Ketone metabolism in AD remains unaffected and could potentially compensate for 
glucose metabolism deficit (121, 149). 
 Ketones result from the mobilization of fatty acids to the liver where they undergo 
conversion from fatty acids to ketones. There are three common manners in which 
serum ketone levels are elevated, 1) through increased mobilization of endogenous 
fatty acids due to prolonged fasting (103), 2) through adherence to a ketogenic diet (KD) 
characterized by fat intake greater than 70% of total energy and reduction of 
carbohydrate to approximately 5% of total energy (104), and 3) through intake of 
ketogenic agents, such as medium-chain triglycerides (MCT), or exogenous ketone 
substrates (105, 106). 
Therapeutic use of the KD in intractable infantile epilepsy is well studied and has 
been extensively applied clinically (150). KD proposal as a potential therapy in AD is not 
novel, however, clinical data are sparse (119, 151, 152). AD patients that consumed an 
MCT, caprylic triglyceride, for 90 days demonstrated elevated beta-hydroxybutyrate 
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(BHB) levels 4-fold by day 90 and had better Alzheimer’s Disease Assessment Scale-
Cognition Subtest (ADASCog) scores than the placebo group (105). Patients diagnosed 
with Mild Cognitive Impairment (MCI) randomized to restriction of carbohydrate as 5-
10% of total energy intake for 6 weeks exhibited elevated urine ketones and improved 
verbal memory scores while no changes were observed in those assigned to the high 
carbohydrate arm of the study (123). Furthermore, feeding of a ketogenic meal to non-
demented elderly positively affected working memory, visual attention, and task 
switching (153). 
The primary aim of the current study was to determine the feasibility of an MCT-
supplemented KD in varying levels of AD. Our secondary aim was to evaluate cognitive 




 In this single-arm pilot clinical study, patients were recruited to follow the MCT-
KD for 3 months. Immediately upon completion of the 3-month dietary intervention, 
participants were asked to discontinue the MCT-KD and resume a normal diet for the 1-
month washout period. 
 
Participants 
 Fifteen older adults with cognition impairment were enrolled in the Ketogenic Diet 
Retention and Feasibility Trial (KDRAFT). Participants were recruited through the 
University of Kansas Alzheimer’s Disease Center. Individuals were eligible to participate 
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in the study if they had a clinical dementia rating (CDR) (125) of very mild AD, CDR 0.5; 
mild AD, CDR 1; or moderate AD, CDR 2, had an active study partner, BMI ≥ 21 kg/m2, 
normal electrolytes and liver function and spoke English. Exclusion criteria included 
serious medical risk including type 1 diabetes, ongoing or recent cancer, cardiac event 
in the past year or other conditions deemed serious risks by physicians on the study 
team. The study protocol was approved by the Institutional Review Board at the 
University of Kansas Medical Center. Informed consent was obtained from all study 
participants per institutional guidelines. 
 
MCT-KD Intervention 
 All participants were assigned to the 3-month MCT-KD dietary intervention. 
Participants received nutrition counseling for the MCT-KD from the study dietitian at the 
baseline study visit. Target macronutrient composition for the dietary intervention 
included approximately 70% of energy as fat, 20% of energy as protein and restriction 
of carbohydrate to less than 10% of energy; a ketogenic ratio of 1:1 (ratio of energy 
from lipid to energy from non-lipid) or better. Energy intake requirement and target daily 
MCT dosage was estimated using the Mifflin-St. Jeor equation (154). A monthly supply 
of MCT oil (Now Foods, USA) was provided at each study visit. MCT dosage titrated 
from 10% of total energy from fat in the first week, increasing by 10% of total energy 
from fat for the subsequent weeks until reaching a target dose of 40% of total energy 
from fat. Participants reached target dosage, but titration rate was adjusted based upon 
participant tolerance. Daily multivitamin, vitamin D, calcium and phosphorus 
supplements were provided to prevent potential micronutrient deficiency. Upon 
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completion of the MCT-KD, participants were instructed to discontinue the MCT-KD to 
complete a 1-month washout period. 
 
Dietary Intake 
 Three-day food records (3DFR) were collected at baseline, month 1, month 2 
and month 3 to characterize dietary intake before, during and after the dietary 
intervention. Each 3DFR recorded intake for 2 weekdays and 1 weekend day. At the 
baseline visit, the study dietitian provided instruction for 3DFR completion. Food record 
data were entered into the Nutrition Data System for Research (NDSR; v. 2016) to 
analyze nutrient intake. 
 
Urinary Ketones 
 Participants self-monitored urinary ketones daily in the early evening using 
urinary acetoacetate test strips (Ketostix, Bayer, Germany). Daily urinary ketone status 
was recorded as either negative, trace, small, moderate or large in a provided diary. 
Days in which participants did not measure ketone levels were conservatively tallied as 
a “negative” ketone response. 
 
Serum Biomarkers 
 All serum biomarkers were collected after a 12 hour fast. A full lipid and 
metabolic panel were collected at baseline and month 3 (end of diet intervention) and 
measured by commercially available kits. Serum BHB and insulin levels were measured 
at all clinical visit time points (baseline, month 1, month 2, month 3 and washout) and 
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quantified using commercially available kits. HOMA2-IR was calculated using HOMA2 
Calculator (v. 2.2.3; University of Oxford, United Kingdom). Blood draws were 
performed by the KU Clinical Translational Science Unit nursing staff and results were 
processed by the KU Hospital Clinical Laboratories. 
 
Cognitive Testing 
 Secondary outcomes included measures of cognition. A trained psychometrician 
administered the Mini-Mental State Exam (MMSE) and the Alzheimer’s Disease 
Assesment Scale Cognitive Subscale (ADAS-cog) at baseline, end of intervention 
(month 3) and after the 1-month washout. The MMSE is a brief, 30-point questionnaire 
designed to identify cognitive impairment (128). The ADAS-cog consists of 11 tasks that 
measure changes in memory, language, praxis and attention (155). Total incorrect 
answers and cued reminders are reported as the cumulative score, thus higher scores 
on the ADAS-cog reflect greater cognitive impairment. 
 
Anthropometric Measures 
 Height, weight and body composition were measured for all subjects by trained 
CTSU staff. Body weight was measured with a calibrated scale (± 0.1 kg). Height was 
measured with a wall-mounted stadiometer. BMI (kg/m2) was calculated using weight 
and height measurements. Dual energy x-ray absorptiometry (DEXA) was used to attain 
and quantify body fat percentage, lean body mass, fat mass and bone mass at baseline 




 Continuous variables were described using their means and standard deviations 
(SD). Descriptive statistics were utilized to quantify and characterize feasibility of the 
intervention. Normality of the dependent variables was assessed through Q-Q 
visualization of residuals models. Paired t-tests were used to analyze differences in 
dietary macronutrient intake prior to and during diet intervention. We constructed linear 
mixed models and tested mean differences with post-hoc pairwise comparisons for 
cognitive data, parametric serum biomarkers. Friedman tests with Conover post-hoc 
pairwise comparisons were performed on serum beta-hydroxybutyrate data. Statistical 
analyses were performed using R (v. 3.3.2; R Foundation, Vienna, Austria). Statistical 




 Fifteen participants meeting the McKhann et al. criteria for AD (156) enrolled in 
the study over the course of 31 months (December 2013-July 2016). Refer to Table 6 
for demographics. 298 individuals with a diagnosis of AD were screened for the study. 
For the first year and 7 months of the enrollment period, potential participants were 
individually identified and screened then contacted by the study coordinator by either 
letter or phone call. Of 72 potential participants contacted, 9 participants enrolled in the 
study. We invited 185 participants by letter to ketogenic cooking demos that were 
offered on 2 different dates. Thirty-eight total potential participants attended 1 of the 2 
cooking demonstrations at the KU Clinical Research Center Demonstration Kitchen, 
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resulting in the enrollment of 6 new participants. Figure 5 depicts the CONSORT 
(http://www.consort-statement.org) profile. 
 























 Mean (SD) 
Age, y 73.1 (9.0) 
Gender (Male/Female) 7 / 8 
BMI, kg/m2 28.3 (6.8) 
Education 15.0 (2.7) 
Clinical Dementia Rating  
     CDR 0.5 7 
     CDR 1 4 
     CDR 2 4 
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Invited to ketogenic 
cooking demo (n=185)




Analyzed as diet-compliant finishers (n=10)
Analyzed as protocol compliant finishers (n=9)
     n=1 participant discontinued cholinesterase
     inhibitor during course of study intervention
Received ketogenic diet intervention for 
duration of study (n=10)
Discontinued diet within first month of study 
due to caregiver burden (n=5)
Received ketogenic diet education and 
intervention (n=15)
Enrolled in study 
(n=9)






Of the participants enrolled in the study, 5 participants did not successfully 
implement the MCT-KD and withdrew from the study within the first month (dropout rate 
of 33%) and provided only baseline data. Four of the dropouts had a diagnosis of 
moderate AD (CDR 2) and the other had a diagnosis of very mild AD (CDR 0.5). Table 
7 summarized the course of the diet and cognitive outcome for each subject. All study 
partners of the participants that withdrew early cited caregiver burden as reason for 
withdrawal from the study. The remaining 10 participants were compliant with the MCT-
KD, however, one participant was considered protocol non-compliant having 
discontinued the cholinesterase inhibitor prescribed for AD symptoms. This was the only 
participant to experience cognitive decline. 
 
Table 7 Individual course of diet 
Subject ID CDR Data for Analysis ADAS-cog1 Time/Reason for Dropout 
01 0.5 X Improve  
02 0.5   Week 2/Caregiver Burden 
05 0.5 X Decline  
06 0.5 X Improve  
07 0.5 X Improve  
11 0.5 X Improve  
13 0.5 X Improve  
08 1 X Improve  
10 1 X Improve  
14 1 X Improve  
15 1 X No change  
03 2   Week 4/Caregiver Burden 
04 2   Week 4/Caregiver Burden 
09 2   Week 5/Caregiver Burden 
12 2   Week 4/Caregiver Burden 
Abbreviations: CDR, clinical dementia rating; ADAS-cog, Alzheimer’s Disease 
Assessment Scale cognitive subscale 
The table demonstrates the participants that completed the 3-month dietary intervention 
as well as individual reasons for dropout and time point. 
1ADAS-cog changes from baseline to month 3. 
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Ten study finishers achieved urinary ketones through the course of the 3-month 
intervention. Self-reported records indicated that finishers attained ketosis an average of 
54.5 ± 29.0 (60.6%) days of the 3-month dietary intervention. Ketones were detected as 
trace (5-14.9 mg/dL)=49%, small (15-39.9 mg/dL)=26%, moderate (40-79.9 
mg/dL)=23% and large (80+ mg/dL)=2% of the total days spent in ketosis. Urinary 
ketone responses were reflected well by serum BHB results with one exception. One 
participant recorded urinary ketones 24.2% only reached trace levels while their serum 
BHB levels were considerably elevated at each study visit. Urinary ketone results are 
presented in Figure 6. 
 Serum BHB was significantly elevated at months 1, 2 and 3 from baseline (0.11 
mmol/L, 0.52 mmol/L, 0.34 mmol/L, 0.31 mmol/L; p<0.001 for each). Serum BHB 
returned to normal at the end of the washout period. Mean and individual BHB values 
are presented in Figure 6. 
 Table 8 contains all values for anthropometric measures, serum biomarkers, 


















Figure 6 Participant ketone measures 
 
A) Mean serum ketone levels at all time points. Serum ketones were significantly 
elevated from baseline at months 1, 2 and 3 (the duration of the MCT-KD intervention). 
B) The individual serum ketone trajectory for all time points. Serum ketone levels 
returned to normal after the 1-month washout period. C) The individual urinary ketone 
results from daily testing. Ketones were detected an average of 54.5 ± 29.0 days. The 
majority of results were trace or small ketones, while some participants recorded 
































































Individual Urinary Acetoacetate Results
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There was no difference in energy intake prior to implementation of versus during 
the MCT-KD dietary intervention. During the intervention, total fat intake increased (fat: 
90.6 g vs. 166.7 g, p < 0.001) and total carbohydrate intake was significantly reduced 
(209.8 g vs. 46.0 g, p < 0.001). The mean macronutrient proportion during the dietary 




















Table 8 Anthropometric, blood-derived and dietary data (n=10) 
 Pre-KD Post-KD P-Value 
Anthropometric Measures    
   Weight, kg 76.5 (17.4) 74.7 (16.2) 0.81 
   BMI, kg/m2 27.7 (7.5) 26.9 (6.8) 0.81 
   Body Fat, % 38.6 (11.5) 38.2 (11.3) 0.94 
   Lean Body Mass, kg 43.5 (7.6) 42.8 (8.6) 0.85 
   Bone Mass, kg  2.7 (0.7) 2.7 (0.7) 0.98 
Lipid Status    
   Total Cholesterol, mg/dL 173.0 (27.5) 194.4 (36.3) 0.16 
   LDL, mg/dL 102.1 (18.7) 117.4 (25.4) 0.14 
   HDL, mg/dL 55.4 (9.2) 58.2 (8.6) 0.49 
Serum Biomarkers    
   AST, U/L 21.1 (5.2) 24.5 (7.0) 0.24 
   ALT, U/L 15.7 (6.5) 18.9 (8.1) 0.34 
   Alkaline Phosphatase, U/L 62.6 (21.3) 55.8 (19.5) 0.48 
   Calcium, mg/dL 9.4 (0.4) 9.5 (0.3) 0.71 
   Chloride, mEq/L 104.1 (1.3) 105.4 (2.2) 0.12 
   Potassium, mEq/L 4.0 (0.3) 4.1 (0.2) 0.47 
   Sodium, mEq/L 137.2 (1.8) 137.9 (1.9) 0.41 
   BUN, mg/dL 20.9 (4.3) 20.1 (6.1) 0.74 
   Creatinine, mg/dL 1.0 (0.2) 1.1 (0.3) 0.58 
Metabolic Status    
   Insulin, µU/mL 5.1 (2.2) 5.0 (2.2) 0.94 
   Glucose, mg/dL 92.6 (5.6) 95.8 (10.0) 0.40 
   HOMA2-IR 0.7 (0.3) 0.7 (0.3) 0.97 
     Beta, % 67.8 (22.1) 62.3 (19.0) 0.56 
     Sensitivity, % 169.6 (51.0) 182.3 (86.4) 0.70 
Dietary Intake    
   Energy (kcal) 1950.7 (450.6) 2002.8 (660.7) 0.80 
   Fat, g 90.6 (23.5) 166.7 (60.0) <0.001 
   Carbohydrate, g 209.8 (80.3) 46.0 (26.9) <0.001 
   Protein, g 81.3 (21.1) 90.0 (28.2) 0.34 
 
Cognition 
 Repeated measures ANOVA was performed to analyze differences in cognitive 
performance at baseline, month 3 and after the 1-month washout period (Figure 7). 
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Including all diet compliant participants (n=10), ADAS-Cog scores significantly improved 
from baseline to month 3 with a mean improvement of 4.1 points (25.5 vs. 21.4, 
p=0.02). Excluding the one protocol non-compliant participant (n=9), ADAS-Cog scores 
improved from baseline to month 3 with a mean improvement of 5.3 points (26.6 vs. 
21.3, p=0.001). Improvements in ADAS-Cog scores diminished during the 1-month 
washout period, with the mean score returning to that similar at baseline (diet compliant 
[n=10]: 21.4 vs. 25.3, p=0.09; excluding protocol non-compliant [n=9]: 21.3 vs. 25.8, 
p=0.05). Excluding the protocol non-compliant participant, MMSE scores significantly 
















Figure 7 Changes in ADAS-Cog scores 
 
A) Mean changes in protocol compliant (n=9) ADAS-Cog scores. Lower ADAS-Cog 
scores indicate cognition improvement. Scores improved 5.3 points from baseline to 
month 3. Improvements at month 3 diminished after the 1-month washout period. B) 
The waterfall plot depicts individual changes in ADAS-Cog scores from baseline to 
month 3 (end of intervention). One participant declined in cognitive performance. This 
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 In this pilot trial, we primarily investigated the feasibility and safety of a 3-month 
medium chain triglyceride ketogenic diet intervention in patients with AD. Secondarily, 
we focused on the effects of the diet on cognition in these patients. The current study 
found the MCT-KD to be feasible as 10 of the 15 participants achieved elevated urinary 
and serum ketone levels and adapted to a carbohydrate restrictive and augmented fat 
nutrient pattern. Furthermore, study finishers achieved the target macronutrient ratio. 
There were no serious adverse events and laboratory and EKG tests raised no safety 
concerns. Mean cognition scores for the participants that successfully implemented the 
MCT-KD improved from baseline to month 3, however, improvements diminished after 
the 1-month washout period. 
 Recruitment and compliance for KD studies in adults can be difficult (157-159). 
Perceptions of the KD border on undesirable, making it difficult to recruit participants via 
traditional contact methods (i.e. letter, phone call, clinic visit). Based upon the current 
study’s recruitment results, we believe that KD therapy studies in adult populations 
require unique, interactive recruitment strategies to generate participation interest. 
Marketing of KD cooking demonstrations generated a great deal more interest and 
immediately showed recruitment benefit – KD preconceptions were altered by allowing 
potential participants and study partners to experience a ketogenic meal and enrollment 
was expedited. It should be noted that limited ketogenic cooking demonstration 
attendance was due to space limitations rather than generated interest. We are 
confident that execution of these recruiting strategies will ease recruitment burden for 
similar future studies. 
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 Five participants withdrew early from the study. These participants were unable 
to successfully implement the KD, indicating to the study dietitian that no ketones were 
achieved via urinary ketone testing. One of the early withdrawals was a CDR 0.5 (very 
mild AD) participant and all 4 CDR 2 (moderate AD) participants withdrew early. 
Caregivers of the CDR 2 participants conveyed that the stress involved in providing care 
to patients with such substantial cognitive change is already stressful and that 
implementing and managing a KD is overwhelming. It is our impression that the MCT-
KD may not be feasible in CDR 2 patients, but quite feasible in AD patients with less 
substantial cognitive change. 
Previously reported side effects of the KD include constipation, nausea, vomiting, 
diarrhea, fatigue and hunger (107). Very few of these symptoms were reported during 
the diet intervention. The most common complaints were nausea and diarrhea, 
seemingly induced by the large consumption of MCT oil. A few participants had 
difficulties titrating to the target MCT dosage, which was resolved by using a blender to 
emulsify the MCT with a longer chain fatty acid food (most commonly grass-fed butter). 
Other nausea complaints were resolved through increased consumption of water. No 
participants complained of hunger or fatigue. 
 Our pilot data provide compelling evidence that the KD provides beneficial effects 
on cognition in patients with AD; however, small sample size and single arm design of 
the current study prevent explicit estimation of the efficacy of the KD treatment on 
cognition. Only one participant experienced cognitive decline while following the diet 
protocol, which was the participant considered protocol non-compliant for discontinuing 
AD medications during the study intervention. Seven participants achieved ADAS-cog 
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improvements with mean improvement exceeding clinical significance (160). Benefit 
diminished after a 1-month washout period, suggesting improvement by those on the 
MCT-KD is unlikely represented by test-retest phenomena; begging the question of how 
quickly potential cognitive improvement relapses upon discontinuance of the diet. Our 
data adds to a very small body of evidence that ketogenic therapies may elicit cognitive 
benefit in individuals with cognition impairment (105, 123). 
 We’ve considered several mechanisms that may have driven the cognitive 
improvements observed in the current study. Brain glucose metabolism deteriorates 
substantially in patients with AD (26, 34, 35). Recent data suggest that brain ketone 
metabolism is positively correlated with serum ketone status (121) and may be 
preserved in the AD brain (35), thus the MCT-KD implemented in the current study may 
have provided the substrate necessary to compensate for cerebral metabolic deficit. 
There are indications that the KD affects mitochondrial function on multiple levels (118). 
The KD has been shown to increase hippocampal mitochondria biogenesis (161). 
Mitochondrial cytochrome oxidase (COX) activity in neurons is downregulated in AD 
(26). Unpublished preliminary data from our group demonstrated that neuronal cells 
increase COX activity when exposed to BHB, which could indicate that ketones induced 
by the MCT-KD may overcome COX activity reduction. Excessive mitochondrial 
production of reactive oxygen species (ROS) has also been observed in AD and the KD 
has been shown to reduce ROS production (124). Furthermore, AD patients exhibit 
elevation in inflammatory markers and our group observed a marked decrease in brain 
TNFa expression in mice fed a KD for 1 month (162). 
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Cognition improvements through insulin mediated pathways have also been 
proposed. Previous data, including data from our group, have demonstrated that 
hyperinsulinemia, insulin resistance and fasting hyperglycemia are associated with brain 
hypometabolism and AD biomarkers (67, 76, 77). A 6-week trial of carbohydrate 
restriction in patients with MCI (123) and a 12-week trial of calorie restriction in elderly 
adults (163) both demonstrated memory improvements that correlated well with 
reduction in fasting insulin levels. While changes in fasting insulin may elicit cognitive 
benefit, it is impossible to establish relationships between changes in insulin and 
cognition from the current study as there was no change in insulin measures and 
participants did not exhibit hyperinsulinemia at baseline. 
KDs appear to have a learning curve as many participants found the diet 
challenging to implement but the difficulty decreased with practice. Essential resources 
are necessary for success at the KD, which will be vital for future studies and clinical 
application of the diet should it be found to be effective in a larger trial. First, a proactive, 
largely available registered dietitian is necessary for proper implementation and 
maintenance of the KD. We believe this to be one of the most important cogs in the 
wheel of this potential therapy’s success. The dietitian for the current study remained 
largely available and maintained frequent contact with participants for support purposes 
and resolution of diet related issues. Finally, we believe an immediate feedback 
mechanism, such as urinary ketone testing, is crucial for participants to evaluate ketone 
status and adjust dietary intake as needed. 
A major strength of this study is its novelty of inclusion of AD participants. 
Another strength involves the elapsed time and washout methodology of cognitive 
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testing to reduce the risk of test-retest phenomena. The current study also has several 
limitations. Conclusions from pilot trials are inherently limited by their small sample size. 
Caution must be exercised in interpretation of cognitive results until a larger efficacy trial 
is conducted. Furthermore, our interpretation that the KD is not feasible in CDR 2 
patients may be pre-emptive due to sample biases. 
Our pilot data demonstrated that the MCT-KD is feasible in AD patients in a less 
advanced stage of the disease and complements previous findings that systemic 
ketosis may be associated with cognitive improvement in cognitively impaired 
individuals. Randomized clinical trials powered to assess efficacy of the KD in AD are 
essential to further investigate KD potential. As treatments for AD are urgently needed, 






































Summary of Findings 
 Several important dietary-related findings were discovered in this dissertation. In 
a sample of 128 cognitively normal individuals, higher intake of high glycemic index 
foods, sugar and carbohydrate was associated with increased cerebral amyloid burden. 
Using principal components analysis to establish dietary patterns, a dietary pattern 
characterized by high glycemic load and sugar intake was strongly associated with 
cerebral amyloid burden. This is concerning because it is projected that by the year 
2050, more than 106 million persons worldwide will have AD (164) and the Western diet 
(high in carbohydrate, sugar and glycemic load) has become much more prevalent on a 
global scale (165). Furthermore, higher sugar intake was associated with poorer 
cognitive performance in this cohort. Next, in a single-arm clinical trial of 15 AD patients 
that consumed a ketogenic diet for 3 months, the carbohydrate restricted, fat 
augmented, ketogenic diet was found to be feasible and elicited substantial cognitive 
improvement. Collectively, manipulating dietary carbohydrate intake may be linked to 




 The research presented from both studies is novel. Dietary carbohydrate, 
glycemic load and sugar intake previously had not been directly linked to amyloid 
burden nor had the ketogenic diet been studied in patients with AD. However, there are 
some major limitations. First, for the observational study, cross-sectional studies are not 
designed to establish causal relationships. Second, although accumulation of amyloid is 
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an identified risk factor for AD, the clinical relevance of amyloid is not precisely 
understood. Third, for the clinical trial, the trial’s power was set up to generate pilot 
efficacy data, therefore one should take caution in drawing specific conclusions from the 
study. Finally, there was not control arm included in the study design. 
 
Future Directions 
 Growing evidence continues to support the hypothesis that Alzheimer’s disease 
is commonly a disease of impaired metabolism. It is vital to understand that behavioral 
traits such as diet, exercise and sleep habits may be crucial pieces to the puzzle of AD 
prevention has led to growing interest in this field of study. 
 As the findings from the observational study presented in this dissertation are the 
first to directly tie carbohydrate, glycemic load and sugar intake to amyloid burden, 
further observational studies should be carried out to further investigate the relationship 
between these dietary components, dietary patterns and amyloid. Beyond this point, it is 
pertinent to better define amyloid’s role in the etiology of AD in order to describe the true 
meaningfulness of the accumulation of this biomarker and the increase in risk due to the 
components that affect its processing. Establishment of new and more thorough 
biomarkers of AD would also be helpful in the advancement of AD prevention studies. 
Although more difficult, clinical trials that manipulate carbohydrate intake and make-up 
could potentially be designed to evaluate changes in AD biomarkers and prevention 
efficacy. There is already a great deal of interest in the Mediterranean diet and DASH 
diet, which are typically lower in glycemic load than global standard diets (166). 
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 Specifically, clinical trials powered to address efficacy of the ketogenic diet in AD 
are needed. To date, two pilot trials have shown cognitive benefit in cognitively impaired 
individuals: 1) a study performed in 12 patients with mild cognitive impairment (123) and 
2) the clinical trial presented in this dissertation. Preferably, a trial design would include 
a more expansive cognitive battery for a more accurate measure of global cognitive 
changes and potentially tease out changes in cognitive compartments. Additionally, 
these studies could include PET imaging techniques to measure cerebral glucose and 
ketone metabolism and elucidate mechanisms by which the ketogenic diet may elicit 
potential beneficial effects. 
 
Closing Statement 
 Because changes in glucose metabolism are observed in AD and even prior to 
diagnosis, the purpose of this research was to better understand how AD is affected by 
carbohydrate type and manipulation of macronutrient intake. The work from this 
dissertation suggests that diet is a crucial component in risk of developing AD and may 
also be utilized as a treatment for those that already have AD. Although much more 
work is necessary to draw scientific conclusions, this research provides compelling 
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Appendix V: KDRAFT Data Collection 
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